NY MED PHARMACEUTICALS PRIVATE LIMITED
NY MED PHARMACEUTICALS PRIVATE LIMITED is a DELHI based PRIVATE LIMITED company, Registered at dated 07-DEC-2018 on Ministry of Corporate Affairs(MCA), The Corporate Identification Number (CIN) of NY MED PHARMACEUTICALS PRIVATE LIMITED is U74999DL2018PTC342722 and registration number is 342722.
It has been classified as COMPANY LIMITED BY SHARES and is registered under Registar of Companies DELHI India. Authorized share capital of NY MED PHARMACEUTICALS PRIVATE LIMITED is Rs. 100000 and its paid up capital is Rs. 100000. It aspire to serve in BUSINESS ACTIVITIES (OTHERS) activities across the India.
Its Annual General Meeting (AGM) was lastly conducted on and as per the records of Ministry of Corporate Affairs (MCA), its balance sheet was last filed on .
NY MED PHARMACEUTICALS PRIVATE LIMITED has 2 directors MOHAMMED ARSHAD SIDDIQUI, MOHAMMED SUALEH SIDDIQUI,
The registered Email address of NY MED PHARMACEUTICALS PRIVATE LIMITED is arsh.sid786@gmail.com and its registered address is HOUSE NO. E-12/21A FIRST FLOOR HAUZ RANI SOUTH DELHI SOUTH DELHI DL 110017 IN DELHI DELHI india 110017.
The current status of NY MED PHARMACEUTICALS PRIVATE LIMITED shows as ACTIVE
COMPANY BASIC DETAILS
NY MED PHARMACEUTICALS PRIVATE LIMITED
DELHI
ACTIVE
BUSINESS ACTIVITIES (OTHERS)
U74999DL2018PTC342722
07 DEC 2018
COMPANY LIMITED BY SHARES
NON-GOVT COMPANY
PRIVATE
100000
100000
CONTACT DETAILS
110017
INDIA
HOUSE NO. E-12/21A FIRST FLOOR HAUZ RANI SOUTH DELHI SOUTH DELHI DL 110017 IN
arsh.sid786@gmail.com
DIRECTOR DETAILS
DIN | Director Name | Designation | Appointment Date |
---|---|---|---|
08297270 | MOHAMMED ARSHAD SIDDIQUI | Director | 07/12/2018 |
08297271 | MOHAMMED SUALEH SIDDIQUI | Director | 07/12/2018 |
Details Updated by Companies
Quick Links
- All Registered company of DELHI
- Company Registered in DELHI
- All Registered company of SOUTH DELHI in DELHI
- Listed Company
- Company Category
- Latest Registered Company
Contact Us for Update Extra Information about your company and services.